Together thesefindings demonstrate that ABPP can provide a unique window on KLKactivity and inhibition in PCa and suggest that KLK-activome dysregulationis a promising and previously underappreciated therapeutic targetin CRPC. The gene discussed is APP; the disease is posterior cortical atrophy.